Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O: Application of genomics in NSCLC. Lung Cancer. 2005, S33-40. 10.1016/S0169-5002(05)81571-5. Suppl 2
Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005, 10: 104-11. 10.1634/theoncologist.10-2-104.
Article
CAS
PubMed
Google Scholar
Mehlen P, Puisieux A: Metastasis: a question of life or death. Nature Rev Cancer. 2006, 6 (6): 449-58. 10.1038/nrc1886.
Article
CAS
Google Scholar
Christofori G: New signals from the invasive front. Nature. 2006, 441: 444-50. 10.1038/nature04872.
Article
CAS
PubMed
Google Scholar
Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B: Expression of xeroderma pigmentosum a protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005, 103 (11): 2313-19. 10.1002/cncr.21031.
Article
CAS
PubMed
Google Scholar
Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res. 2000, 6: 4797-4802.
CAS
PubMed
Google Scholar
Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncology. 2005, 16 (10): 1646-1653. 10.1093/annonc/mdi316.
Article
CAS
Google Scholar
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groschen S, Cohen H, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol. 1996, 14: 176-82.
CAS
PubMed
Google Scholar
Vogel U, Dybdahl M, Frentz G, Nexo BA: DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 2000, 461: 197-210.
Article
CAS
PubMed
Google Scholar
Kwon HC, Roh M, Oh S, Kim SH, Kim M, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007, 18: 504-9. 10.1093/annonc/mdl430.
Article
PubMed
Google Scholar
Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Eng J Med. 2006, 335 (10): 983-991. 10.1056/NEJMoa060570.
Article
Google Scholar
Park DJ, Lenz HJ: Determination of chemosensitivity in gastric cancer. Curr Opin Pharmacol. 2006, 6: 337-344. 10.1016/j.coph.2006.05.002.
Article
CAS
PubMed
Google Scholar
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63: 6221-8.
CAS
PubMed
Google Scholar
Rosell R, Cecere F, Santarpia M, Reguart N, Taron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006, 6: 323-331. 10.1016/j.coph.2006.01.011.
Article
CAS
PubMed
Google Scholar
Mullan PB, Quinn JE, Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 2006, 25: 5854-63. 10.1038/sj.onc.1209872.
Article
CAS
PubMed
Google Scholar
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Nat Cancer Inst. 2004, 96: 1659-68.
Article
CAS
PubMed
Google Scholar
Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004, 13: 2443-9. 10.1093/hmg/ddh260.
Article
CAS
PubMed
Google Scholar
Kennedy RD, Quinn JE, Johnston PG, Harkin DP: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet. 2002, 360: 1007-14. 10.1016/S0140-6736(02)11087-7.
Article
CAS
PubMed
Google Scholar
Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H: Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 2006, 26: 695-702.
CAS
PubMed
Google Scholar
Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995, 55: 5276-82.
CAS
PubMed
Google Scholar
Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U, Dermatologic Cooperative Oncology Group: In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group. Clin Cancer Res. 2006, 12: 5454-63. 10.1158/1078-0432.CCR-05-2763.
Article
CAS
PubMed
Google Scholar
Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, amont A, Gulliford T, Hurren J, Yiangou C, Cree IA: Cancer cell adaptation to chemotherapy. BMC Cancer. 2005, 5: 78-10.1186/1471-2407-5-78.
Article
PubMed
PubMed Central
Google Scholar
Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human cancer cells. J Bio Chem. 1998, 273 (36): 23419-23425. 10.1074/jbc.273.36.23419.
Article
CAS
Google Scholar
Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B: Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat. 2005, 94: 71-80. 10.1007/s10549-005-7328-3.
Article
CAS
PubMed
Google Scholar
Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006, 95: 1390-5. 10.1038/sj.bjc.6603428.
Article
CAS
PubMed
PubMed Central
Google Scholar
Neragi-Miandoab S: Malignant pleural effusion. Current and evolving approaches for its diagnosis and management. Lung cancer. 2006, 54: 1-9. 10.1016/j.lungcan.2006.04.016.
Article
PubMed
Google Scholar
Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG: Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer. 2007, 96: 241-7. 10.1038/sj.bjc.6603538.
Article
CAS
PubMed
PubMed Central
Google Scholar